ARTIS Ventures

An excellent example of how the latest advances in AI/ML can help move the needle for patients to meaningfully improve outcomes. Grateful to partner with Senan Ebrahim, MD, PhD and the entire Delfina team to solve the maternal health crisis once and for all!

In 2001, ARTIS Ventures made a commitment to support visionary founders at the nexus of technology and the life sciences. Since that time, the opportunity to support transformative growth across the TechBio+Health ecosystem has served as the driving force behind our work. Conceivable Life Sciences is an outstanding example of how innovation drives essential advancements in healthcare. The team’s flagship product, AURA, is the world’s first end-to-end automated IVF lab. Built on decades of experience in robotics, artificial intelligence (AI), machine vision, and embryology, AURA promises the hope to achieve superior clinical outcomes and standardization while reducing costs and making high-quality care more accessible to the millions of infertile couples around the world who currently lack treatment options. We could not be more proud to join Joshua Abram, Alan Murray, Alejandro Chavez-Badiola, MD, PhD, and the entire Conceivable team in celebrating the close of an $18 million Series A financing as they advance clinical trials and gear up for a U.S. commercial launch next year. Leading this round has been nothing short of a privilege thanks to our stellar colleagues at Atlantic Health System Venture Studio, Muse Capital, and Scrub Capital. Congratulations to Conceivable, to existing investors ACME Capital, Black Opal Ventures, Cadence Healthcare Ventures, Future Positive Capital, Stride.VC, Time BioVentures, and to the patients who will directly benefit from this transformative new era in reproductive care. Check out the full press release for more: https://lnkd.in/ehFxe4_a Stuart Peterson?Omair Khan

ARTIS Ventures recently led a $15M Series A into Luminate Medical, led by Aaron Hannon. We're excited at their potential to transform the chemotherapy treatment process by reducing side effects for patients, lowering costs for payers, and unlocking value for private practice oncologists across the United States. Welcome to the Artis portfolio family!

Delix Therapeutics will initiate Phase Ib and Phase II studies in major depression in 2024 and 2025, respectively. #techbio #Biotech #psychedelics

Nature Portfolio shines a light on the good work being done by Unnatural Products Inc.

Last week, we had the pleasure of hosting our inaugural NeuroTech dinner for pioneering entrepreneurs and scientists who are building innovative technologies at the forefront of neuroscience. The event was a melting pot of perspectives, where key opinion leaders discussed topics including: ???? How academic and industrial labs can work together to best drive innovation? ???? Advancements that could come from detailed structural mapping of the brain?? ???? The role advancements in machine learning will play in future neuroprosthetic devices It was a delightful evening of electric discussions and camaraderie that left us more excited than ever about what the future holds! A special thanks to all who attended, including Doris Tsao, Max H., Anish Mitra, Milan Cvitkovic, Sumner L Norman, Vikash Gilja, Mei Z., David Moses, Amy Rochford, Erin Kunz, Guy Wilson, Raman Vilkhu, Austin Walne, Vasudev Bailey, and Stuart Peterson.

Congrats to Eko Health and the team! Honored to be a part of this journey as you work to change the face of heart disease and save countless lives.

Millions of people worldwide are affected by cancer. To meet the demand for cancer-treating therapies, Siren Biotechnology is developing a universal AAV immuno-gene therapy platform designed to reduce development and manufacturing timelines, while also working for numerous types of cancer. As part of the award, Siren Biotechnology will receive a wide range of support from MilliporeSigma, including Millipore??bioprocessing products, technologies and consultative services, and close partnership with the company to screen different media formulations to help optimize AAV yield. #techbio #oncology #lifesciences #biotech #genetherapy

Their latest funding and support by Khosla Ventures further establishes Rad AI's credibility in the generative AI space and expands the team's ability to become the indisputable leader across the healthcare AI market. We’re excited to welcome Vinod Khosla and Khosla Ventures to support Rad AI’s next stage of growth.? Congratulations again to Doktor Gurson, Dr. Jeff Chang, and the Rad AI team on the exciting road ahead!? #generativeai #healthcare #radiology #techbio

Over the past decade, ARTIS has continued to focus its energies and resources on the growing opportunity to deliver frontier technologies, specifically AI, to the worlds of healthcare and biology. As investors who care deeply about both value creation and societal impact, it’s gratifying when founders we supported early in their development achieve significant milestones toward positively impacting patient outcomes. That’s especially true with today’s news of Rad AI’s $50M Series B, led by Khosla Ventures. Congrats to Doktor Gurson, Jeff Chang, and the entire team!